SRZNW
Get informed when a big investor buys or sells
+ FollowUndervalued by 63588.2% based on the discounted cash flow analysis.
| Market cap | $195.98 Million |
|---|---|
| Enterprise Value | $95.85 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-32.37 |
| Beta | 0.59 |
| Outstanding Shares | 10,949,000 |
| P/E Ratio | -0.84 |
|---|---|
| PEG | 0.84 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | 12.79 |
| Enterprise Value to EBIT | -0.92 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | -0.02 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 180,8090% |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 26.68%▼ 6.89% |
|---|---|
| Total Invested | $46,744▼ 18.78% |
| Investors Holding | 18▲ 1.00% |
No data
Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Wnt signaling plays key roles in the control of development, homeostasis, and regeneration of many essential organs a...